Attenuation of MPTP-induced dopaminergic neurotoxicity by a serotonin uptake blocker.
Attenuation of MPTP-induced dopaminergic neurotoxicity by a serotonin uptake blocker.
复制标题
通过血清素摄取阻滞剂减弱 MPTP 诱导的多巴胺能神经毒性。
DOI：
10.1007/bf01245250
复制
发表时间：
1988
影响因子：
3.3
通讯作者：
Wagner,GC
中科院分区：
文献类型：
--
作者：
Brooks,WJ;Jarvis,MF;Wagner,GC
Monoamine oxidase-B (MAO-B) has been determined to be the enzyme responsible for the conversion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into its toxic metabolite 1-methyl-4-phenylpyridine ion (MPP+). Since this enzyme has been localized primarily in astrocytes and serotonergic neurons, it would appear that MPP+ is being produced outside the dopaminergic neurons. To investigate this possibility, the administration of MPTP was preceded by systemically administered fluoxetine. In keeping with its demonstrated ability to inhibit uptake into serotonergic neurons and serotonin uptake into astrocytes, fluoxetine pretreatment resulted in a significant attenuation of MPTP-induced depletions of striatal dopamine and serotonin concentration. These results support the extra-dopaminergic production of MPP+.
